M&A

News

Boehringer buys cancer immunotherapy firm T3 for $507m

Germany’s Boehringer Ingelheim has made a move to expand its cancer pipeline via a takeover of T3 Pharma, a spinout from the University of Basel in Switzerland.

News

MSD reaches $610m deal to buy lysosome biotech Caraway

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases.

News

Digital health company BehaVR hits the merger trail again

Less than a year after joining with OxfordVR to create a specialist in digital therapeutics (DTx) for mental illnesses, BehaVR has expanded into the chronic pain category

News

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Galapagos has signed a deal to jettison its troubled JAK inhibitor drug Jyseleca, agreeing to sell the rights to rheumatoid arthritis and ulcerative colitis therapy to Ita

News

Rumour confirmed as Roche buys Telavant for $7.1bn

Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t

News

EU clears path for Pfizer’s takeover of Seagen

Pfizer’s $43 billion acquisition of antibody-drug conjugate specialist Seagen has been given the go-ahead by the authorities in the EU, clearing a key remaining obstacle t

Boehringer buys cancer immunotherapy firm T3 for $507m

MSD reaches $610m deal to buy lysosome biotech Caraway

Digital health company BehaVR hits the merger trail again

Alfasigma to buy Galapagos’ JAK drug for up to €170m

Rumour confirmed as Roche buys Telavant for $7.1bn

EU clears path for Pfizer’s takeover of Seagen

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

M&A

Editor's Picks